Palvella Therapeutics

Q2 FY2026 EarningsQ2 FY26 net loss of -$21.9M was wider than the consensus estimate of -$16.8M, resulting in a GAAP EPS miss of -$1.52 vs. -$1.18 expected. R&D and G&A expenses surged YoY as the company accelerated QTORIN™ rapamycin’s rolling NDA submission and prepared for a potential H1 2027 commercial launch. Despite the bottom-line miss, the company maintains a robust cash position of $250.6M, providing significant runway for its upcoming Phase 3 trials and commercial infrastructure build-out.